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Backkground: Hemophagocytic lymphohistiocytosis (HLH)
is a life-threatening condition characterized by prolonged
fever, hepatosplenomegaly, cytopenia, and hemophagocy-
tosis. Primary HLH is considered fatal unless treated by
hematopoietic stem cell transplantation (HSCT).
Method: Herein we report six Iranian patients as a case
series with primary HLH and their outcome from a single
tertiary-care center Between 2000-2012.
Results: Griscelli syndrome type 2 (GS2) was diagnosed in 3
patients based on clinical, laboratory, and microscopic
features of partial albinism and ﬁnding of RAB27Amutations
in 2 patients tested. Two patients were on the HLH-2004
continuation therapy and waiting for HSCT, but no matched
donor yet: The ﬁrst case is in 2nd remission after 1.5 years;
he had history of relapse in maintenance phase of HLH-2004
protocol which more immunosuppressive treatment was
advised. The second case is in remission after 1 year. Two
other patients died, while waiting for a suitable donor: case 3
had history of recurrent HLH and died after 6 months; and
the case 4 had history of progression to T-cell ALL after 2
years and dead due to relapse of ALL, sepsis and DIC despite
chemotherapy after 3 years. Two patients underwent HSCT;
patient 5 had a HLA-identical sibling donor and patient 6 had
a cord blood-, unrelated, one antigen mismatched donor.
Both patients were treated according to the HLH-2004
treatment protocol and none had active disease at the time of
HSCT. Patient 5 who were diagnosed with GS2 responded
well and remained in remission through 24 months of
follow-up, while another case died because of graft-versus-
host disease and infection on day 136 after HSCT.
Conclusion: HSCT seems to be the only curative treatment
for primary HLH which drastically improve survival of the
patients. Making a deﬁnite diagnosis conﬁrmed by gene
mutation studies is helpful to provide genetic counseling and
prenatal diagnosis and, more important, dictate the need for
HSCT later in the patient's course.
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Aim: Following Hematopoietic stem cell transplantation
(HSCT), the accurate monitoring of donor-derived cells
prospectively is critical for understanding sustained
engraftment or whether therapeutic intervention is needed,
in turn predicting the success or failure of HSCT.We designed
a highly sensitive, quantitative PCR (qPCR) research assay
speciﬁcally for engraftment monitoring following HSCT in
a research setting. It can accurately detect recipient cells up
to 0.01% while also reducing workﬂow and analysis burdens
as compared to routine STR testings. To enable broader
access to the AlleleSEQR qPCR Chimerism Assay RUO across
more clinical research laboratories, we have assessed
performance of the multiplexed screening assay across ﬁve
different qPCR platforms from four manufacturers.Method: A panel of 34 qPCR research assays to bi-allelic
indels across the genome enables informative marker iden-
tiﬁcation and quantiﬁcation to occur within a few hours and
without the need for capillary electrophoresis. To decrease
our current sample volume requirements, increase
throughput and enable multiple donor screening scenarios
across multiple transplantation centers, we evaluated
a multiplexed assay approach for marker identiﬁcation
utilizing ﬁve different qPCR platforms. The alleles are scored
in relation to ampliﬁcation of an endogenous control assay
and 6-8 samples can be evaluated simultaneously across all
platforms.
Results: Multiplexing the assays to 2-4 assays/well yielded
identical results when compared to single well 34 assays. In
addition, using ﬁve different qPCR platforms i.e. Applied
Biosystems 7500 and ViiA7 Real-Time PCR System, Qiagen
Rotor-Gene Q, Focus 3M Integrated Cycler and Roche
LightCycler 480 System, the described multiplexed qPCR
approach yielded results with 100% concordance in identi-
fying informative markers on six unique Coriell DNA across
platforms.
Conclusions: The results from this multiplexed qPCR
research system for screening of informative markers were
100% concordant to results generated when using the assays
individually. Performance of the multiplex qPCR assays were
independent of the platform providing supportive results for
possible future use in transplant centers.397
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Introduction: Patients with acute myelogenous leukemia
(AML) or non responsive myelodysplastic syndrome (MDS)
who fail to achieve a complete remission, have unfavorable
cytogenetics or are refractory to therapy have a poor prog-
nosis. Allogeneic HSCT is frequently considered a salvage
option for these patients although remissions are short-lived.
New strategies are needed for maintaining remission in this
extremely high risk patient group. We hypothesized hypo-
methylating agents post allogeneic HSCT would enable
patients to remain in complete remission.
Methods: Eleven patients were treated. Patient characteris-
tics: median age, 48 years (range, 18-70 years), PBSC (n¼9) or
bone marrow (n¼2); Diagnoses AML¼ 10, Non- responsive
MDS¼1, CIBMTR disease risk category: High [n¼8], Inter-
mediate [n¼1], Low [n¼2]; 36% of the patients had primary
induction failure, 54% had complex molecular abnormalities
with 18% of the patients having deletion 11q 23 molecular
abnormalities. Donors were unrelated (36%) and related
(64%). All but 1 donor-recipient pairs were fully matched.
Preparative regimen- busulfan based (16mg/kg or equiva-
lent) (82%), TBI  12 Gy (9%) based or reduced-intensity
haplo-identical regimen (9%). The median number of prior
chemotherapy regimens was 2.5 (range, 2-6). Azacitidine
(n¼10) or decitabine (n¼1) was selected at physician
discretion as a planned prophylactic regimen post allogeneic
HSCT engraftment. Initial starting doses were based on
hematological conditions at the time of therapy initiation.
Results: Ten patients received azacitidine subcutaneously
daily for seven days for a median of 5 cycles (range, 1-10
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venously for 5 days for 3 cycles. Median initial Azacitidine
dose of 50 mg/m2 (range, 25-75 mg/m2) were given at
a median of 40 days (range, 38-101 days) post HSCT
engraftment. Azacitidine doses were increased based on
counts to a maximum dose of 75mg/m2. With a median
follow-up of 24months (range, 1.7-49 months) 6 patients are
alive in complete remission. Twenty-four month progression
free survival is 51% with overall survival of 76%.
Conclusion: Given the dismal results of progression free
survival and overall survival following allogeneic HSCT in
high risk AML or non responsive MDS, hypomethylating
agents given post transplantation provide a valuable
approach to prolonging remission.398
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Engraftment among allogeneic HCT recipients is associ-
ated with endothelial damage, cytokine release and elevated
white count. The impact of persistent leukocytosis after
engraftment on survival and transplant related complica-
tions such as graft versus host disease is not well established.
In this study, we retrospectively reviewed the charts of 74
consecutive patients who underwent allogeneic HCT in
a single center between 2009 and 2011. Neutrophil engraft-
ment was deﬁned as an absolute neutrophil count of
0.5x103/ml for 3 consecutive days. Patients’ blood counts
were assessed for 60 days post engraftment (three times per
week). Persistent Leukocytosis (group A) was deﬁned as
a white blood cell count of >10 x103 /ml for more than four
different blood draws. Patients who had leukocytosis for
three or less blood draws were called group B. Conditioning
regimens included myeloablative MA (Fludarabine/Busulfan
or cytoxan/total body irradiation) and reduced intensity RIC
(ﬂudarabine/busulfan or ﬂudarabine/cytoxan/low dose TBI).
Graft versus host disease prophylaxis included metho-
trexate/tacrolimus for myeloablative and tacrolimus/Myco-
phenolate for reduced intensity conditioning.
The median age was 51 years (range: 18-74 years). Graft
source included matched related (n¼24), Unrelated donor(n¼48) and cord blood (n¼2). 36 patients received MA
conditioning and 37 had RIC conditioning. Median follow up
for the cohort was 556 days. Median time to neutrophil
engraftment was 13 days. 22 patients had persistent leuko-
cytosis (group A) during the ﬁrst 60 days post engraftment.
The two groups did not differ in terms of age, gender, diag-
nosis (acute leukemia versus other), disease risk and condi-
tioning regimen (table 1). Group A had a higher proportion of
related donor source (50% versus 31%; P ¼ .05). One year
overall survival was signiﬁcantly worse in group A (40.6%
versus 74.7%; P ¼ .009). Grade II-IV acute graft versus host
disease was higher among group A patients (68% versus 48%;
P ¼ .18) although not statistically signiﬁcant. The cause of
death among patients with persistent leukocytosis included
acute GVHD (n¼6), relapse (n¼5), infection (n¼2) and
thrombosis (n¼1).
In conclusion, Persistent leukocytosis post engraftment in
allo-HCT recipients is associated with worse overall survival
and may be an independent risk factor for acute GVHD.
Despite a larger proportion of related donors among the
leukocytosis group, our data showed a trend towards higher
incidence of acute GVHD. The exact mechanism leading to
prolonged leukocytosis is not clear and further studies to
conﬁrm the association between leukocytosis and clinical
outcomes are warranted.399
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The aim of this study was to determine the incidence,
clinical features and outcome of invasive fungal disease (IFD)
after either an unmanipulated haploidentical hematopoietic
stem cell transplantation (HSCT) or a human leukocyte
antigen (HLA)-matched sibling HSCT. This was a head-to-
head comparative study performed at a single center.
Patients were admitted between 2007 and 2010, and IFDwas
evaluated according to the revised EORTC/MSG criteria, with
only proven and probable cases included. Of the 1,042
consecutive patients enrolled, 390 received the HLA-
matched HSCT and 652 received an unmanipulated hap-
loidentical HSCT. A total of 61 (5.8%) patients had IFD, which
was broken down into 15 proven cases and 46 probable
cases. The median time of diagnosis was 35 days (range
6-405) after transplantation. Themost common involved site
was the lung (52/61), and Aspergillus was the most common
(18/29) pathogen. The incidence of IFD after an unmanipu-
lated haploidentical HSCT was signiﬁcantly higher than the
HLA-matched transplant (7.1% versus 3.3%, respectively,
P ¼ .007), which was caused by the more early IFD (before
day 40). IFD occurred later in patients receiving an HLA-
matched transplant compared to patients receiving the
unmanipulated haploidentical HSCT (141.5 versus 23 days,
respectively, P ¼ .04). The response to therapy and the
mortality rate corresponding to IFD were similar between
the two types of transplantation. In conclusion, patients
received an unmanipulated haploidentical HSCT had higher
risk of IFD than those patients received an HLA-matched
HSCT, but the prognosis of IFD was not associated with the
HLA type.
